Deregulated MicroRNA Signature Following Glioblastoma Irradiation

Eman A. Toraih, MD, PhD1,2, Aya El-Wazir, MBBCh, MSc1,2, Hoda Y. Abdallah, MD, PhD1,2, Mohamed A. Tantawy, PhD3, and Manal S. Fawzy, MD, PhD4,5

Abstract
Glioblastoma (GBM), the most common and aggressive brain tumor in adults, shows resistance to treatment, particularly radiotherapy. One method for effective treatment is using a group of radiosensitizers that make tumor cells responsive to radiotherapy. A class of molecules whose expression is affected by radiotherapy is the microRNAs (miRNAs) that present promising regulators of the radioresponse. Eighteen miRNAs (miR-26a, -124, -128, -135b, -145, -153, -181a/b, -203, -21, -210, -212, -221/222, -223, -224, -320, and -590), involved in the pathogenesis of GBM and its radioresponsive state, were reviewed to identify their role in GBM and their potential as radiosensitizing agents. MicroRNAs-26a, -124, -128, -145, -153, -181a/b, -203, -221/222, -223, -224, -320, and -590 promoted GBM radiosensitivity, while microRNAs-135b, -21, -210, and -212 encouraged radioresistance. Ectopic overexpression of the radiosensitivity promoting miRNAs and knockdown of the radioresistant miRNAs represent a prospective radiotherapy enhancement opportunity. This offers a glimmer of hope for a group of the most unfortunate patients known to medicine.

Keywords
Glioblastoma, microRNAs, radioresistance, radiosensitivity, review

Received September 13, 2018. Received revised December 31, 2018. Accepted for publication April 3, 2019.

Introduction
Glioblastoma (GBM) is the most common and lethal brain tumor in adults.1,2 It is a grade IV tumor characterized by a heterogeneous population of cells that are genetically unstable, highly infiltrative, angiogenic, and resistant to chemotherapy and radiotherapy.3 Exploring the mechanisms underlying tumor resistance and recurrence is warranted to design future molecularly targeted therapies.2

The current first-line therapy is surgical resection, followed by a combination of the chemotherapeutic agent temozolomide (TMZ) and regional fractionated ionizing radiation (IR).4 In addition, personalized therapeutic modalities against molecular deregulated targets that drive tumor growth have been tried in several clinical trials. However, almost all patients with GBM undergo inevitable tumor recurrence.1,3 This could be attributed to the incomplete resection of the infiltrative tumor tissues, as well as the extensive hypoxic nature of GBM tumors that limits the efficiency of chemotherapy and radiotherapy.5,6

Multiple factors can affect resistance to radiotherapy, for example, tumor location, size, microenvironment, and most

1 Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2 Center of Excellence of Molecular and Cellular Medicine, Suez Canal University, Ismailia, Egypt
3 Department of Hormones, Medical Research Division, National Research Centre, Cairo, Egypt
4 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
5 Department of Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia

Corresponding Authors:
Eman A. Toraih, Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. Email: emantoraih@gmail.com
Manal S. Fawzy, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. Email: manal2_khashana@ymail.com
importantly, genetic influences. Some of the major genetic elements regulating tumorogenesis as well as the radioresistance are microRNAs (miRNAs). In the following sections, we will address the role of miRNAs in GBM and the differential miRNA genomic landscape of pre- and posttreated GBM cells for a better understanding of the miRNA-related tumor regression and resistance.

**MicroRNAs: Key Players in Glioblastoma**

MicroRNAs are small noncoding RNA molecules that regulate gene expression at a posttranscriptional level by either cleaving or repressing the translation of messenger RNA targets via binding to complementary sequence. They control various cellular processes including apoptosis, proliferation, cell cycle, invasion, and angiogenesis. Several miRNAs have been recently reported to be involved in modulation of GBM development and progression. The miRNAs can function as oncogenes or tumor suppressors according to the genes or pathways that they target. Emerging evidence demonstrated the potential role of miRNAs in the response of chemotherapy and radiotherapy, a finding that opens new avenues for identifying potentially more effective therapeutic targets in an attempt of improving patient survival.

**Role of MicroRNAs in Modulation of Radiosensitivity in Glioblastoma**

Radiotherapy is widely used in cancer treatment and biological studies where the IR damages cancer cells through producing free radicals and intermediate ions that cause single- or double-stranded breaks in the DNA. This usually triggers activation of the DNA damage response, which is one of the main reasons of radioresistance.

DNA, however, is not the only component affected by radiation, where growing evidence suggests that radiation can disturb the expression of miRNAs. Since miRNAs regulate DNA repair, cellular homeostasis, and response to stress, they can modulate the radiosensitivity of GBM tumor cells. In that context, miRNAs could have the potential to be either radiosensitizers or radioprotectors.
Multiple miRNAs deregulated in GBM were found to affect the tumor response to radiotherapy. The mechanisms of those miRNAs in GBM are displayed in Figure 1 and reviewed below together with their association with IR.

**MicroRNAs Involved in Radiosensitivity Enhancement in GBM**

**MicroRNA-26a.** In GBM, miRNA-26a (miR-26a) was frequently amplified at the DNA level in human glia.\(^{18}\) It was found to promote low expression of the tumor suppressors phosphatase and tensin homolog (PTEN) and retinoblastoma 1.\(^{18}\) Furthermore, Guo et al showed that overexpression of miR-26a can enhance radiosensitivity and reduce the DNA repair ability of cells by targeting ataxia–telangiectasia mutated (ATM) gene with subsequent inhibition of the homologous recombination repair pathway. In contrast, miR-26a knockdown in U87 GBM radiosensitive cells reverses this phenotype.\(^{20}\)

**MicroRNA-124.** MicroRNA-124 (miR-124), a brain-specific miRNA, was identified to be markedly downregulated in human brain glioma.\(^{21,22}\) It could function as a tumor suppressor in glioma stem cells (GSCs) by negatively regulating tumor cell proliferation and invasion.\(^{23}\) Downregulation of miR-124, frequently encountered in GBM cells, could mediate tumorigenesis, promote cancer stem cell self-renewal, and enhance radiation resistance through targeting the oncogenes Bmi-1 and SUZ12, 2 members of the polycomb repressor complex (PRC).\(^{24,25}\) Ye et al\(^{25}\) reported that low expression of miR-128 in U87 GBM cells following high doses of irradiation enhanced the escape of cells from radiation-induced senescence resulting in radioreistance. However, miR-128 upregulation decreased the expression of PRC genes and rendered GSCs more sensitive to radiation.\(^{26}\)

**MicroRNA-145.** Another tumor suppressor, microRNA-145 (miR-145), has been reported to be downregulated in GBM. The recovery of its expression level can induce apoptosis via targeting B-cell lymphoma/leukemia-2 (Bcl-2) and myeloid cell leukemia sequence 1 proteins.\(^{33}\) Upregulation of miR-153 suppressed the oxidative stress transcription factor nuclear factor erythroid 2-related factor 2 and increased reactive oxygen species level, with subsequent enhancement of apoptosis, differentiation, and radiosensitivity in GSCs in vitro and increased survival in mice bearing human GSCs.\(^{26,32}\)

**MicroRNA-181a/b.** MicroRNA-181a/b (miR-181a/b), members of the miR-181 family, was one of the downregulated miRNAs in U87GBM cells.\(^{33}\) In response to radiation treatment, the radiation-responsive miR-181a was significantly overexpressed transiently, leading to malignant glioma (MG) cell sensitization to radiotherapy via targeting the apoptotic regulator Bcl-2 protein.\(^{33}\)

**MicroRNA-203.** MicroRNA-203 (miR-203), another known cancer-associated miRNA, was downregulated in glioma and correlated with prognosis.\(^{34}\) Overexpression of miR-203 increased the radiation sensitivity in U251, U373, and T98G human MG cell lines, prolonged radiation-induced γ-H2AX (H2A Histone Family Member X) foci formation, which is an indicator of double-strand DNA damage, and inhibited DNA damage repair by downregulating ATM and modulating AKT and STAT3 signaling pathways.\(^{35}\) Moreover, upregulated miR-203 suppressed invasion, epithelium–mesenchyme transition, and migration potentials via inhibiting prosurvival signaling, neural crest transcription factor SLUG (a member of the Snail family of zinc finger transcriptional repressors), has been implicated in the acquisition of invasive behavior during tumor progression, and the intermediate filament protein (Vimentin) and increasing the expression of the senescence-associated epithelial membrane protein 1 (Claudin-1) and the tight junction protein (Zona Occludens 1).\(^{26,35,36}\) Therefore, miR-203 could potentially contribute to the modulation of radiation sensitivity in MG cell lines.\(^{26}\)

**MicroRNAs-221/222.** MicroRNAs-221/222 (miR-221/222) play key roles in modulating DNA damage response.\(^{26}\) In GBM tissues and cells, miR-221/222 were found to be upregulated and correlated with the stage of disease.\(^{37}\) They regulate glioma tumorigenesis and invasiveness through the control of protein phosphatase PTPμ.\(^{37}\) In contrast, transfection with miR-221/222 antisense oligonucleotides halted GBM proliferation in the U251 human glioblastoma cell line and U251 glioma subcutaneous mice.\(^{38}\) Knocked down cells exhibited cell cycle arrest via increasing the cell cycle inhibitor p27Kip1 which in turn suppressed G1/S shift in the cell cycle in vitro and in vivo\(^{38}\) and reduced tumor volume in a GBM xenograft mouse model.\(^{26}\) Combining anti-miR-221/222 with tumor irradiation synergistically enhanced mitotic cell death and decreased S-phase fraction.\(^{38}\)
MicroRNA-223. MicroRNA-223 (miR-223) was identified as a key regulator in cancer cell differentiation, proliferation, adhesion, and motility via targeting several proteins as forkhead box O1 transcription factor and insulin-like-growth factor 1 receptor, expression of erythrocyte membrane protein band 4.1-like 3, and F-box/WD repeat-containing protein 7. In U87 MG cells, miR-223 overexpression downregulates the serine/threonine kinase ATM expression and sensitizes U87 cells to radiation in vitro and in vivo, thus highlighting its putative utility as a cancer-targeting therapy.

MicroRNA-224. The influence of microRNA-224 (miR-224) on cell growth has been well characterized in GBM cell lines and primary GBM tumor tissues. Low expression level in patients with GBM was associated with poor prognosis. Exogenous introduction of miR-224 reduced clonogenic potential of U87GBM cells by 30% to 55% with a more synergistic effect reaching 85% to 90% upon combination with irradiation with a dose of 6G that when applied solely produced a 50% reduction. Therefore, miR-224 increased radiation sensitivity in GBM tumor partially by targeting apoptosis inhibitor 5 gene.

MicroRNA-320. MicroRNA-320 (miR-320) has been demonstrated to be closely correlated with the development of glioma. Downregulated miR-320 along with upregulated forkhead box protein M1 was encountered in radioresistant glioma tissues and cells. However, miR-320 overexpression dramatically enhanced radiosensitivity, promoted apoptosis, and improved γH2AX expression and caspase 3 activity in glioma cells through downregulation of sirtuin 1.

MicroRNA-590-3p. MicroRNA-590-3p (miR-590-3p) was reported as a mediator for glioma initiation and development. Its upregulation was observed in high-grade glioma tissues and radioresistant human GBM cells (U251 R) through targeting leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1). Inhibiting miR-590-3p promoted radiosensitivity of U251 R cells by enhancing apoptosis and suppressing cell viability.

MicroRNAs Involved in Radioresistance in GBM

MicroRNA-21. MicroRNA-21 (miR-21) profile was observed to be significantly increased in MG cell lines and tissues, promoting cell survival, tumor growth, and chemoresistance. It is one of the major players in glioma radioresistance through the regulation of autophagy. It was upregulated 1.4.9-fold in radioresistant cell line SHG-44 (R) relative to the SHG-44 cells. Application of anti-miR-21 resulted in radiosensitization of U373 and U87 cells, whereas overexpression of miR-21 led to a decrease in radiosensitivity of LN18 and LN428 cells. Moreover, knockdown of miR-21 combined with tumor irradiation synergistically enhanced mitotic death and apoptosis in glioma cell lines and xenograft tumor models. Blocking miR-21 decreased the expression of the epidermal growth factor receptor, phospho-AKT, caspase-3, cyclin D, and Bcl-2, as well as induced cell cycle arrest and autophagy.

MicroRNA-210. High expression of microRNA-210 (miR-210) was found in some types of cancer, especially in GBM. It is involved in cell survival, stemness maintenance, and hypoxia adaptation and its expression is modulated by hypoxia inducible factor and nuclear factor κB. It regulates cell proliferation and apoptosis via targeting regulator of differentiation 1 in GBM cells. Knockdown of miR-210 increased the apoptotic rate, reduced the antioxidant capacity, and sensitized hypoxic GSCs following irradiation. Thus suggesting the putative beneficial role of combining miR-210 inhibition and radiotherapy to halt GBM cells.

MicroRNA-212. MicroRNA-212 (miR-212) revealed inconsistent altered expression patterns in various types of tumors. However, in GBM, it functioned as a tumor suppressor whose expression was significantly downregulated. Overexpression of miR-212 decreased viability of GBM cells in vitro and suppressed tumor growth in vivo by directly targeting serum and glucocorticoid-inducible kinase 3 (SGK3). In human U251 and SHG-44 GBM cells, miR-212 was identified as negatively associated radiation-induced microRNA that was downregulated following γ-ray exposure. Transfection of miR-212 mimic in irradiated U251 and SHG-44 GBM cells has shown to attenuate radiation-induced apoptosis, alter the expression of apoptosis-related proteins (downregulation of Bcl-2 and upregulation of cleaved-caspase-3), and increase colony formation ability in response to radiation, hence suggesting its contribution in radioresistance via targeting breast cancer susceptibility gene 1.

MicroRNA-135b. The tumor suppressor microRNA-135b (miR-135b) was recognized to play a critical role in GBM development. It was the most downregulated microRNA in patient-derived GBM stem-like cells, and its restoration decreased tumorigenic potentiality and reduced brain infiltration in GBM animal models. However, miR-135b expression was found to be upregulated in the U87R radio-GBM cell line compared to parent U87 cells. Its knockdown increased radiosensitivity by direct regulation of glycogen synthase kinase-3b (GSK3β), a negative regulator of cell growth. Similarly, in patients with GBM, miR-135b overexpression and GSK3β downregulation were encountered in recurrent tumors compared to primary ones after treatment with IR, highlighting the correlation of miR-135b/ GSK3β axis with radiotherapy.

Functional Enrichment Analysis

Taking into consideration the “off-target phenomenon” associated with miRNA therapy, we used DIANA tools to investigate the miRNA molecular target pathways and gene ontology and define how each miRNA can influence the downstream signaling pathway in each target. Radiotherapy-related miRNAs were analyzed, and ontology terms were filtered according to the significance of the interaction (P < .01) and intersected as depicted in Figure 2. Among the 18 selected miRNAs, miR-320 and miR-210, modulators for radiosensitivity and radioresistance, respectively, were involved in few
biological processes, which could indicate minimal off-target effects upon using these miRNAs in therapeutic purpose.

**MicroRNA Delivering System in Glioblastoma**

Micro-RNA-based therapies (miRNA mimics or antagonists) could be delivered locally or systemically in the form of naked or modified nucleic acids, conjugated with lipids and other molecules or carried in various forms of nanoparticles and vectors. However, such therapies present several challenges including inadequate penetration to tumor cells, miRNA degradation and reduced half-life, undesired effects on other genes, and systemic toxicities. Although the blood–brain barrier, which limits passage of miRNAs to the brain tissue, represents another major hurdle in GBM, some studies have described effective miRNA therapy techniques. For instance, Shatsberg et al used miR-34a nanogels in mice with human GBM cell line U-87 MG and succeeded in suppressing tumor progression. Malhotra et al adopted cyclic arginine-glycine-aspartic-targeted poly(lactic-co-glycolic acid) nanoparticles in GBM mouse models and reported an enhancement in therapeutic response to TMZ. Also noted was the in vitro and in vivo...
inhibition of GBM growth after using ribonucleoprotein containing anti-miR-21. Delivery through mesenchymal stem cells has also proved worthwhile in GBM. Further clinical trials are required to test the side effects of such therapies.

Conclusions and Prospectives
Taken together, miR-26a, miR-124, miR-128, miR-145, miR-153, miR-181a/b, miR-203, miR-221/222, miR223, miR-224, miR-320, and miR-590-3p increase the radiosensitivity of GBM cells, while miR-21, miR-210, miR-212, and miR-135b decrease it. Therefore, overexpressing the former group or knocking down the latter group could help increase the response of GBM cancer cells to radiotherapy, ultimately contributing to cancer control and improving patient survival.

Acknowledgments
The authors thank the science and technology development fund (STDF) for providing the facilities for ongoing work.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Manal S. Fawzy https://orcid.org/0000-0003-1252-8403

References
1. Osaka S, Van Meir E. Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest. 2017;127(2):415-426. doi:10.1172/JCI89587.
2. Louis D.N, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1.
3. Wen P, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507. doi:10.1056/NEJMra0708126.
4. Ramirez Y, Weatherbee J, Wheelhouse R, Ross A. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuti-cals [Basel]. 2013;6(12):1475-1506. doi:10.3390/ph6121475.
5. Hall E, Giaccia A. Radiobiology for the Radiologist. 7th ed. New York, NY; Philadelphia, PA: Lippincott; Williams & Wilkins; 2012. https://trove.nla.gov.au/version/51355121
6. Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol. 2011;38(suppl 4):2-10. doi:10.1053/j.seminoncol.2011.09.005.
7. Deng X, Ma L, Wu M, et al. miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol. 2013;114(3):263-274. doi:10.1007/s10660-013-1179-2.
8. Toraie EA, Ibrahim AT, Fawzy MS, Hussein MI, Al-Qahtani SAM, Shaalan AAM. MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma. Oxid Med Cell Longev. 2017;2017:3269379. doi:10.1155/2017/3269379.
9. Fawzy MS, Toraie EA, Ibrahim A, Abdeldayem H, Mohamed AO, Abdel-Daim MM. Evaluation of miRNA-196a2 and apoptosis-related target genes: ANXA1, DFFA and PDCD4 expression in gastrointestinal cancer patients: a pilot study. PLoS One. 2017;12(11):e0187310. doi:10.1371/journal.pone.0187310.
10. Toraie EA, Aly NM, Abdallah HY, et al. MicroRNA-targets cross-talks: key players in glioblastoma multiforme. Tumour Biol. 2017;39(11):1-22. doi:10.1177/1010428317726842.
11. Toraie EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. Mol Diagn Ther. 2015;19(3):179-190. doi:10.1007/s40291-015-0143-6.
12. Zhao L, Bode A, Cao Y, Dong Z. Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carci-nogenesis. 2012;33(11):2220-2227. doi:10.1093/carcin/bgs235.
13. Ni J, Bucci J, Chang L, Malouf D, Graham P, Li Y. Targeting microRNAs in prostate cancer radiotherapy. Theranostics. 2017;7(13):3243-3259. doi:10.7150/thno.19934.
14. Natarajan V. Regulation of DNA repair by non-coding miRNAs. Noncoding RNA Res. 2016;1(1):64-68. doi:10.1016/j.ncrna.2016.10.002.
15. Galatenko V, Galatenko A, Samatov T, et al. Comprehensive network of miRNA-induced intergenic interactions and a biological role of its core in cancer. Scientific Reports. 2018;8:2418. doi:10.1038/s41598-018-20215-5.
16. Leung A, Sharp P. MicroRNA functions in stress responses. Mol Cell. 2010;40(2):205-215. doi:10.1016/j.molcel.2010.09.027.
17. He X, Fan S. Hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1. Oncol Rep. 2018;39(3):977-984. doi:10.3892/or.2017.6156.
18. Huse J, Brennan C, Hambardzumyan D, Wee B. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009;23(11):1327-1337. doi:10.1101/gad.1777409.
19. Kim H, Huang W, Jiang X, Pennicooke B, Park P, Johnson M. Integrative genome analysis reveals an oncomir/onco gene cluster regulating glioblastoma survivorship. Proc Nat Acad Sci USA. 2010;107(5):2183-2188. doi:10.1073/pnas.0909896107.
20. Guo P, Lan J, Ge J, et al. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res. 2014;320(2):200-208. doi:10.1016/j.yexcr.2013.10.020.
21. Ciufre S, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochim Biophys Res Commun. 2005;334(4):1351-1358. doi:10.1016/j.bbrc.2005.07.030.
22. Silber J, Lim D, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;24:14. doi:10.1186/1741-7015-6-14.
23. Chen PH, Cheng CH, Shih CM, et al. The inhibition of microRNA-128 on IGF-1-activating mTOR signaling involves in temozolomide-induced glioma cell apoptotic death. PLoS One. 2016;11(11):e0167096. doi:10.1371/journal.pone.0167096.
24. Peruzzi P, Bronisz A, Nowicki M, et al. MicroRNA-128 coordinately targets Polycomb repressor complexes in glioma stem cells. *Neuro Oncol*. 2013;15(9):1212-1224. doi:10.1093/neuonc/not055.

25. Ye L, Yu G, Wang C, et al. MicroRNA-128a, Bmi1 polycomb ring finger oncogene, and reactive oxygen species inhibit the growth of U-87 MG glioblastoma cells following exposure to X-ray radiation. *Med Mol Rep*. 2015;12(4):6247-6254. doi:10.3892/mmr.2015.4175.

26. Han X, Xue X, Zhou H, Zhang G. A molecular view of the radioresistance of gliomas. *Oncotarget*. 2017;8(59):100931-100941. doi:10.18632/oncotarget.21753.

27. Du Y, Li J, Xu T, Zhou DD, Zhang L, Wang X. MicroRNA-145 is downregulated from small RNA deep sequencing. *BMC Genomics*. 2011.10.071.

28. Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. *Neuromolecular Med*. 2014;16(2):517-528. doi:10.1007/s12017-014-8305-y.

29. Lee H, Bier A, Cazacu S, et al. MicroRNA-145 is downregulated in glioblastoma: insights materials.2011.10.004.

30. Yang Y, Chien Y, Chiou G, et al. Inhibition of cancer stem cell migration and invasion of glioblastoma by targeting miR-145. *Biomaterials*. 2012;33(5):1462-1476. doi:10.1016/j.biomaterials.2011.10.071.

31. Agrawal R, Pandey P, Jha P, Dwivedi V, Sarkar C, Kulshreshtha R. Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing. *BMC Genomics*. 2014;15:686. doi:10.1186/1471-2164-15-686.

32. Yang W, Shen Y, Wei J, Liu F. MicroRNA-153/Nrf-2/GPx1 pathway regulates radioresistance and stemness of glioma stem cells via reactive oxygen species. *Oncotarget*. 2015;6(26):22006-22027. doi:10.18632/oncotarget.4292.

33. Chen G, Zhu W, Shi D, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bel-2. *Oncol Rep*. 2010;23(4):997-1003. doi:10.3892/or_00000725.

34. He J, Li Y, Xie X, Wang L, Chun S, Cheng W. hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide. *Exp Ther Med*. 2013;5(5):1315-1321. doi:10.3892/etm.2013.981.

35. Chang J, Hwang Y, Lee D, et al. MicroRNA-203 Modulates the radiation sensitivity of human malignant glioma cells. *Int J Radiat Oncol Biol Phys*. 2016;94(2):412-420. doi:10.1016/j.ijrobp.2015.10.001.

36. Zhou Y, Yan G, Spizzo R, et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. *Mol Oncol*. 2014;8(1):83-92. doi:10.1016/j.molonc.2013.09.004.

37. Quintavalle C, Garofalo M, Zanca C, et al. miR-221/222 overexpression in human glioblastoma increases invasiveness by targeting the protein phosphate PTP Mu. *Oncogene*. 2012;31(7):858. doi:10.1038/onc.2011.280.

38. Zhang C, Kang C, You Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. *Int J Oncol*. 2009;34(6):1653-1660. doi:10.3892/ijo_0000296.

39. Liang L, Zhu J, Zazorsky N, et al. MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. *Int J Radiat Oncol Biol Phys*. 2014;88:955-960. doi:10.1016/j.ijrobp.2013.12.036.

40. Upadhyay S, Kazi S, Padul V, Shirsat N. MiR-224 expression increases radiation sensitivity of glioblastoma cells. *Biochem Biophys Res Commun*. 2014;448:225-230. doi:10.1016/j.bbrc.2014.04.095.

41. Li T, Ma J, Han X, et al. MicroRNA-320 enhances radiosensitivity of glioma through down-regulation of sirtuin type 1 by directly targeting forkhead box protein M1. *Transl Oncol*. 2018;11:205-212. doi:10.1016/j.tranon.2017.12.008.

42. Chen L, Wang W, Zhu S, et al. MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1. *Exp Ther Med*. 2017;14:1818-1824. doi:10.3892/etm.2017.4697.

43. Chao T, Xiong H, Liu W, Chen Y, Zhang J. MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. *J Hua Zhong Univ Sci Technolog Med Sci*. 2013;33:525-529. doi:10.1007/s11596-013-1153-4.

44. Gwak H, Kim T, Jo G. Silencing of microRNA-21 releases epidermal growth factor receptor pathway through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. *PLoS One*. 2012;7:e47449. doi:10.1371/journal.pone.0047449.

45. Zhou J, Zhou C, Wang L, Xu X, Qin S. Influence of knock-down of miR-21 expression on the radiosensitivity of glioma SHG-44 cells. *Zhonghua Zhong Liu Za Zhi*. 2011;33:747-751. doi:10.3760/cma.j.issn.0253-3766.2011.10.006.

46. Zhou X, Ren Y, Moore L, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. *Lab Invest*. 2010;90:144-155. doi:10.1038/labinvest.2009.126.

47. Shang C, Hong Y, Guo Y, Liu Y, Xue Y. MiR-210 up-regulation enhances proliferation and induces apoptosis in glioma cells by targeting SIN3A. *Med Sci Monit*. 2014;20:2571-2577. doi:10.12659/MSM.892994.

48. Liu Y, Han, Zhang H, et al. Synthetic miRNA-mowers targeting miR-183–96–182 cluster or miR-210 inhibit growth and migration of glioma cells independent of PTEN status. *Lab Invest*. 2012;7:e47280. doi:10.1371/journal.pone.0052280.

49. Kim J, Park S, Song S, Kim J, Sung J. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. *Cell Death Dis*. 2013;4:e588. doi:10.1038/cddis.2013.117.

50. Huang X, Le Q, Giaccia A. MiR-210-micromanager of the hypoxia pathway. *Trends Mol Med*. 2010;16:230-237. doi:10.1016/j.molmed.2010.03.004.

51. Zhang S, Lai N, Liao K, Sun J, Lin Y. MicroRNA-210 regulates expression and migration of glioma stem cells by targeting ATM. *Int J Radiat Biol*. 2015;91:1043-1051. doi:10.1080/09133312.2015.1016004.

52. Fang W, Wei J, Guo T, Shen Y, Liu F. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and...
radioresistance. *Exp Cell Res*. 2014;326:22-35. doi:10.1016/j.yexcr.2014.05.022.

53. Liu H, Li C, Shen C, et al. MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. *J Neurooncol*. 2015;122:431-439. doi:10.1007/s11060-015-1736-y.

54. Lulli V, Buccarelli M, Martini M, et al. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. *Oncotarget*. 2015;6:37241-37256. doi:10.18632/oncotarget.5925.

55. Xiao S, Yang Z, Lv R, et al. miR-135b contributes to the radioresistance by targeting GSK3β in human glioblastoma multiforme cells. *PLoS One*. 2014;9:e108810. doi:10.1371/journal.pone.0108810.

56. Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. *Nucleic Acids Res*. 2015;43:W460-W466. doi:10.1093/nar/gkv403.

57. Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. *Adv Drug Deliv Rev*. 2014;81:128-141. doi:10.1016/j.addr.2014.05.009.

58. Purow B. The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?. *J Neurooncol*. 2010;103:429-436. doi:10.1007/s11060-010-0449-5.

59. Shatsberg Z, Zhang X, Ofek P, et al. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. *J Control Release*. 2016;239:159-168. doi:10.1016/j.jconrel.2016.08.029.

60. Malhotra M, Sekar TV, Ananta JS, et al. Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model. *Oncotarget*. 2018;9:21478-21494. doi:10.18632/oncotarget.25135.

61. Lee TJ, Yoo JY, Shu D, et al. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. *Mol Ther*. 2017;25:1544-1555. doi:10.1016/j.ymthe.2016.11.016.

62. Lee HK, Finniss S, Cazacu S, Xiang C, Brodie C. Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression. *Stem Cells Dev*. 2014;23:851-861. doi:10.1089/scd.2014.0146.

63. Sharif S, Ghahremani MH, Soleimani M. Delivery of exogenous miR-124 to glioblastoma multiform cells by Wharton’s jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemosensitivity. *Stem Cell Rev*. 2018;14:236-246. doi:10.1007/s12015-017-9788-3.